QuidelOrtho Projects $80 Million in Annual Savings by 2027 Amid Revenue Guidance Adjustments
QuidelOrtho (QDEL) management reported that while the underlying business remains resilient, the company is facing significant near-term headwinds. These challenges include pricing pressures in China and a decline in respiratory testing demand. Consequently, the company has narrowed its 2026 revenue guidance to a range of $2.52 billion to $2.54 billion. To offset these pressures, QuidelOrtho is implementing cost-efficiency measures aimed at achieving over $80 million in annual savings by 2027. The company's leadership remains focused on navigating current market volatility through strategic launches and operational improvements.
Tickers: $QDEL
Topics: China market pricing earnings report respiratory testing revenue headwinds
Read the full article at Seeking Alpha
Part of the story QuidelOrtho Projects $80 Million in Annual Savings by 2027 Amid Revenue Guidance Adjustments (2 articles)